All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityEquity IPOs

IPO investors pay up for Freeline as biotech fever rises


Freeline, the UK gene therapeutics company, has priced its IPO on the Nasdaq exchange at the top of the pricing range, with investors willing to pay a big premium for the stock. The company is the latest deal in a global biotech issuance spree that has passed $60bn.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login